Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Curosurf plus early nasal CPAP versus early nasal CPAP alone in very preterm infants at risk of respiratory distress syndrome
2006-004105-25Phase 4Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Incidence of need for mechanical ventilation within the first 5 days of life. Started Dec 2006; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2006-004105-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004105-25.